**Drug Therapy Protocols: Amiodarone**

**Disclaimer and copyright**
©2018 Queensland Government

All rights reserved. Without limiting the reservation of copyright, no person shall reproduce, store in a retrieval system or transmit in any form, or by any means, part or the whole of the Queensland Ambulance Service (‘QAS’) Clinical practice manual (‘CPM’) without the prior written permission of the Commissioner.

The QAS accepts no responsibility for any modification, redistribution or use of the CPM or any part thereof. The CPM is expressly intended for use by QAS paramedics when performing duties and delivering ambulance services for, and on behalf of, the QAS.

Under no circumstances will the QAS, its employees or agents, be liable for any loss, injury, claim, liability or damages of any kind resulting from the unauthorised use of, or reliance upon the CPM or its contents.

While effort has been made to contact all copyright owners this has not always been possible. The QAS would welcome notification from any copyright holder who has been omitted or incorrectly acknowledged.

All feedback and suggestions are welcome, please forward to: Clinical.Guidelines@ambulance.qld.gov.au

<table>
<thead>
<tr>
<th>Date</th>
<th>April, 2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Purpose</td>
<td>To ensure a consistent procedural approach to Amiodarone administration.</td>
</tr>
<tr>
<td>Scope</td>
<td>Applies to all QAS clinical staff.</td>
</tr>
<tr>
<td>Author</td>
<td>Clinical Quality &amp; Patient Safety Unit, QAS</td>
</tr>
<tr>
<td>Review date</td>
<td>April, 2021</td>
</tr>
<tr>
<td>Information security</td>
<td>This document has been security classified using the Queensland Government Information Security Classification Framework (QGISCF) as UNCLASSIFIED and will be managed according to the requirements of the QGISF.</td>
</tr>
</tbody>
</table>

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
**Drug class**

Anti-arrhythmic

**Pharmacology**

Amiodarone prolongs the duration of the action potential and therefore the refractory period of atrial, nodal and ventricular tissues. It also reduces conduction across all cardiac tissue – including myocardial and conducting system cells. Amiodarone demonstrates electrophysiological properties across all Vaughan-Williams Class groups, which enables a broad spectrum of activity.[1–3]

**Metabolism**

The majority of amiodarone is excreted via the liver and GI tract by biliary excretion; there may be some hepatic recirculation.

**Indications**

- **Cardiac arrest** (refractory VF OR pulseless VT)[4]
- **Sustained conscious VT** (haemodynamically stable)

**Contraindications**

- **Cardiac arrest** (refractory VF OR pulseless VT):
  - Nil
- **Sustained conscious VT** (haemodynamically stable):
  - Allergy and/or Adverse Drug Reaction
  - severe conduction disorders (unless pacemaker or AICD in situ)
  - current amiodarone therapy
  - concurrent anti-arrhythmic therapy that prolongs the QT interval
  - pregnancy and/or lactation

**Precautions**

- **Cardiac arrest** (refractory VF OR pulseless VT):
  - concurrent anti-arrhythmic therapy that prolongs the QT interval[5]
  - thyroid disease
- **Sustained conscious VT** (haemodynamically stable):
  - hypotension
  - thyroid disease[2,6]
**Amiodarone**

### Side effects
- Hypotension\(^1,2\)
- Bradycardia
- Nausea and/or vomiting
- Peripheral paraesthesia

### Routes of administration
- Intravenous injection (IV)
- Intraosseous injection (IO)
- Intravenous infusion (IV INF)

### Presentation
- Ampoule, 150 mg/3 mL amiodarone

### Onset (IV) | Duration (IV) | Half-life
--- | --- | ---
5 minutes | 30 minutes | 14–110 days (with chronic dosing)

### Schedule
- S4 (Restricted drugs).

### Special notes
- If the patient is on oral amiodarone, the following cardiac arrest administration protocols continue to be authorised.
- If lidocaine (lignocaine) has been administered to a patient with conscious VT that progresses into cardiac arrest, the following administration protocols continue to be authorised.
- If the patient is in Torsade de Pointes due to suspected prolonged QT interval from excess amiodarone administration, magnesium sulphate administration is to be considered.
- After completion of a risk/benefit analysis, the QAS authorises the administration of sodium chloride 0.9% (flush or running IV line) following amiodarone administration in cardiac arrest, despite manufacturer’s recommendations.
Adult dosages (cont.)

Cardiac arrest (refractory VF OR pulseless VT)

<table>
<thead>
<tr>
<th>Method</th>
<th>Dosage</th>
<th>Administration</th>
<th>Total Maximum Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>IV</td>
<td>300 mg</td>
<td>Slow push over 2 minutes. Repeated once at 150 mg after 5 minutes.</td>
<td>450 mg</td>
</tr>
<tr>
<td>IO</td>
<td>300 mg</td>
<td>Slow push over 2 minutes. Repeated once at 150 mg after 5 minutes.</td>
<td>450 mg</td>
</tr>
</tbody>
</table>

Sustained conscious VT (haemodynamically stable)

<table>
<thead>
<tr>
<th>Method</th>
<th>Dosage</th>
<th>Administration</th>
<th>Syringe Preparation</th>
</tr>
</thead>
<tbody>
<tr>
<td>IV INF</td>
<td>300 mg</td>
<td>Infusion over 30 minutes. Administer via SPRINGFUSOR® 30 mL.</td>
<td>Mix 300 mg amiodarone (6 mL) with 24 mL of glucose 5% in a 30 mL SPRINGFUSOR® syringe to achieve a final concentration of 300 mg /30 mL. Ensure syringes are appropriately labelled. Administer via SPRINGFUSOR® 30 mL at a rate of 60 mL/hour (over 30 minutes).</td>
</tr>
</tbody>
</table>

CCP ESOp aeromedical – RSQ Clinical Coordinator consultation and approval required in all situations.
Continue amiodarone infusions already commenced at hospital, using the same concentration and administration rate already established. This may involve withdrawing previously mixed and labelled solutions prepared from the referring hospital.
Should the RSQ Clinical Coordinator request an amiodarone infusion be commenced, the following procedure is to be undertaken.

**Loading dose – 300 mg over 30 minutes**

Syringe preparation: Mix 300 mg (6 mL) of amiodarone with 44 mL of glucose 5% in a 50 mL syringe to achieve a final concentration of 6 mg/mL. Ensure all syringes are appropriately labelled. Administer via syringe driver at a rate of 100 mL/hour (over 30 minutes).

**Maintenance dose – 900 mg over 24 hours**

Syringe preparation: Mix 150 mg (3 mL) of amiodarone with 47 mL of glucose 5% in a 50 mL syringe to achieve a final concentration of 3 mg/mL. Ensure all syringes are appropriately labelled. Administer via syringe driver at the rate of 12.5 mL/hour. Maintenance infusion is to be commenced immediately following the loading dose and is to continue for a period of 24 hours with a total of 900 mg amiodarone administered.
Paediatric dosages

**Cardiac arrest** (refractory VF or pulseless VT)

<table>
<thead>
<tr>
<th>Route</th>
<th>Dose</th>
<th>Administration</th>
<th>Preparation</th>
</tr>
</thead>
<tbody>
<tr>
<td>IV</td>
<td>5 mg/kg</td>
<td>Slow push over 2 minutes. Single dose only.</td>
<td>Mix 150 mg (3 mL) of amiodarone with 12 mL of glucose 5% (totalling 15 mL) in a 20 mL syringe to achieve a final concentration of 10 mg/mL.</td>
</tr>
<tr>
<td>IO</td>
<td>5 mg/kg</td>
<td>Slow push over 2 minutes. Single dose only.</td>
<td>Mix 150 mg (3 mL) of amiodarone with 12 mL of glucose 5% (totalling 15 mL) in a 20 mL syringe to achieve a final concentration of 10 mg/mL.</td>
</tr>
</tbody>
</table>